for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quest Diagnostics Inc

DGX.N

Latest Trade

105.89USD

Change

1.08(+1.03%)

Volume

80,401

Today's Range

104.88

 - 

105.97

52 Week Range

78.97

 - 

107.95

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
104.81
Open
105.03
Volume
80,401
3M AVG Volume
19.85
Today's High
105.97
Today's Low
104.88
52 Week High
107.95
52 Week Low
78.97
Shares Out (MIL)
134.67
Market Cap (MIL)
14,114.77
Forward P/E
16.14
Dividend (Yield %)
2.02

Next Event

Q3 2019 Quest Diagnostics Inc Earnings Release

Latest Developments

More

Quest Diagnostics Inc Files For Potential Debt Shelf Offering, Size Undisclosed

Quest Diagnostics Says American Medical Collection Agency Notified Co, Optum360 Of Potential Unauthorized Activity On Amca's Web Payment Page

Quest Diagnostics Sets Quarterly Cash Dividend Of $0.53 Per Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

Industry

Healthcare Facilities

Contact Info

500 Plaza Dr

+1.973.5202700

https://www.questdiagnostics.com/

Executive Leadership

Stephen H. Rusckowski

Chairman of the Board, President, Chief Executive Officer

Mark J. Guinan

Chief Financial Officer, Executive Vice President

James E. Davis

Executive Vice President, General Diagnostics

Gabrielle Wolfson

Senior Vice President and Chief Information and Digital Officer

Michael E. Prevoznik

Senior Vice President, General Counsel

Key Stats

2.53 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

7.5K

2017

7.7K

2018

7.5K

2019(E)

7.7K
EPS (USD)

2016

5.150

2017

5.670

2018

6.310

2019(E)

6.495
Price To Earnings (TTM)
20.34
Price To Sales (TTM)
1.86
Price To Book (MRQ)
2.59
Price To Cash Flow (TTM)
13.60
Total Debt To Equity (MRQ)
72.83
LT Debt To Equity (MRQ)
58.05
Return on Investment (TTM)
7.45
Return on Equity (TTM)
6.32

Latest News

Latest News

Virginia top court rules Quest whistleblower owed cut of gross settlement

The Virginia Supreme Court has ruled that whistleblowers who sue companies for defrauding the state's Medicaid program are entitled to have their cut of any settlement that results be based on the gross proceeds rather than state's net share.

BRIEF-Quest Diagnostics Adds Helen Torley To Board Of Directors

* QUEST DIAGNOSTICS - HELEN TORLEY ELECTED TO SERVE AS DIRECTOR AT CO'S 2018 ANNUAL MEETING OF STOCKHOLDERS, EXPANDING BOARD OF DIRECTORS TO 10 MEMBERS Source text for Eikon: Further company coverage:

BRIEF-Quest Diagnostics Says CEO Rusckowski's 2017 Total Compensation Was $10.35 Mln Vs $10.25 Mln In 2016

* QUEST DIAGNOSTICS INC SAYS CEO STEPHEN H. RUSCKOWSKI'S 2017 TOTAL COMPENSATION WAS $10.35 MILLION VERSUS $10.25 MILLION IN 2016 – SEC FILING Source text: (https://bit.ly/2uKsWVj) Further company coverage:

BRIEF-Quest, Humana, Multiplan, Optum, UnitedHealthcare Launch Blockchain Program

* Quest - CO, HUMANA, MULTIPLAN, UNITEDHEALTH GROUP'S OPTUM, UNITEDHEALTHCARE LAUNCH BLOCKCHAIN PROGRAM TO IMPROVE DATA QUALITY AMONG OTHERS Source text for Eikon: Further company coverage:

BRIEF-Genomic Vision Extends Its Collaboration With Quest Diagnostics​

* GENOMIC VISION EXTENDS ITS COLLABORATION WITH QUEST DIAGNOSTICS IN SPINAL MUSCULAR ATROPHY (SMA)

BRIEF-Quest Diagnostics Reports Q4 Adjusted Earnings Per Share $1.40

* QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2018; INCREASES DIVIDEND 11% TO $0.50 PER QUARTER

BRIEF-Fresenius Medical Care Closes Divestment Of Shiel Medical Laboratory To Quest Diagnostics

* DGAP-NEWS: FRESENIUS MEDICAL CARE CLOSES DIVESTMENT OF SHIEL MEDICAL LABORATORY TO QUEST DIAGNOSTICS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Quest Diagnostics provides update on impact of 2018 Medicare payment rates

* Quest Diagnostics provides update on impact of final 2018 Medicare payment rates for clinical laboratory tests

BRIEF-FDA approves Clinical Genomics, Quest Diagnostics Insure One

* Clinical Genomics and Quest Diagnostics announce FDA 510(k) clearance of Insure® One™

BRIEF-Quest Diagnostics acquires certain assets of California Laboratory Associates

* Quest Diagnostics acquires California Laboratory Associates

BRIEF-Advantage Capital Portfolio company Cleveland Heartlab acquired by Quest Diagnostics

* Advantage Capital Portfolio company Cleveland Heartlab, Inc acquired by Quest Diagnostics

BRIEF-Quest Diagnostics reports Q3 diluted eps of $1.15

* Quest Diagnostics reports third quarter 2017 financial results, updates 2017 financial guidance and reaffirms long term outlook

BRIEF-Fresenius Medical Care says divests Shiel Medical Laboratory to Quest Diagnostics

* Deal to generate modest book gain for Fresenius Medical Care

BRIEF-Quest Diagnostics provides update on impact to 3rd quarter financial results from hurricanes

* Quest Diagnostics provides update on impact to third quarter financial results from hurricanes

Fitch Affirms Quest Diagnostics at 'BBB'; Outlook Stable

(The following statement was released by the rating agency) NEW YORK, September 27 (Fitch) Fitch Ratings has affirmed the ratings of Quest Diagnostics Incorporated (NYSE: DGX) including the Issuer Default Rating (IDR) at 'BBB'. The Rating Outlook is Stable. A full list of...

Quest to offer cholesterol testing without fasting requirement

Quest Diagnostics Inc said on Thursday it will begin using a more precise method of calculating levels of "bad" LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up...

BRIEF-Quest Diagnostics to acquire Cape Cod Healthcare outreach laboratory business

* Quest Diagnostics announces intent to acquire Cape Cod Healthcare outreach laboratory business in Massachusetts

BRIEF-Quest Diagnostics reports Q1 revenue of $1.9 bln

* FY2017 earnings per share view $5.46 -- Thomson Reuters I/B/E/S

BRIEF-Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017

* Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017

BRIEF-QUEST DIAGNOSTICS SAYS WILL ACQUIRE OUTREACH LABORATORY SERVICES OPERATIONS OF PEACEHEALTH LABORATORIES

* QUEST DIAGNOSTICS AND PEACEHEALTH FORMED TWO-PART ARRANGEMENT TO ENHANCE DELIVERY OF LABORATORY SERVICES TO COMMUNITIES IN OREGON, WASHINGTON, ALASKA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up